SCHEMBL3707984

SCHEMBL3707984

CCC1O[C@@H]1CCCC/C=C\CCCCCCCCCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
PPARG P37231 4/20 0.57
PPARD Q03181 4/20 0.57
PPARA Q07869 4/20 0.57
F7 P08709 4/20 0.57
F3 P13726 4/20 0.57
TERT O14746 3/20 0.57
PTPN1 P18031 3/20 0.57
BLM P54132 3/20 0.57
HSD17B10 Q99714 3/20 0.57
CYP19A1 P11511 3/20 0.57
FABP4 P15090 2/20 0.57
LMNA P02545 2/20 0.57
ALOX15 P16050 2/20 0.57
RECQL P46063 2/20 0.57
PTGS1 P23219 2/20 0.57
KMT2A Q03164 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
DUSP3 P51452 2/20 0.57
PTPN7 P35236 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704192 1.00 MAPT (0.57) MAPTPPARGPPARDPPARAF7
SCHEMBL18212571 1.00 MAPT (0.57) MAPTPPARGPPARDPPARAF7
SCHEMBL3702710 1.00 MAPT (0.57) MAPTPPARGPPARDPPARAF7
SCHEMBL7031615 1.00 MAPT (0.57) MAPTPPARGPPARDPPARAF7
SCHEMBL3703727 0.97 MAPT (0.57) MAPTPPARGPPARDPPARAF7
SCHEMBL3704145 0.95 MAPT (0.58) MAPTPPARGPPARDPPARAF7
SCHEMBL3704911 0.95 MAPT (0.58) MAPTPPARGPPARDPPARAF7
SCHEMBL11538646 0.90 GPR84 (0.48) PPARGPPARDPPARAPTPN1HSD17B10
SCHEMBL2482201 0.90 GPR84 (0.48) PPARGPPARDPPARAPTPN1HSD17B10
SCHEMBL3746335 0.88 MAPT (0.54) MAPTPPARGPPARDPPARAF7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365183-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2022-06-21 US disclosed
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-10-17 US disclosed
US-10287262-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-05-14 US disclosed
EP-3222612-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2017-09-27 EP disclosed
EP-2376432-B1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) 2017-04-12 EP disclosed
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2016-11-10 US disclosed
US-9272991-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2016-03-01 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4873/4885PPARG 72/4885PPARD 80/4885
US-10287262-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 MAPT 4861/4885PPARG 58/4885PPARD 55/4885
US-11365183-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 MAPT 4861/4885PPARG 58/4885PPARD 55/4885
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4864/4885PPARG 72/4885PPARD 73/4885
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4864/4885PPARG 72/4885PPARD 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.